Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
02.08. | Health Canada grants approval for Celltrion's Steqeyma for multiple conditions | ||
01.08. | Jade Biosciences secures $80m to develop autoimmune therapies | ||
31.07. | Pinetree secures $17m to advance TPD development programmes | ||
30.07. | FDA approves Alpha Cognition's ZUNVEYL for Alzheimer's treatment | ||
29.07. | LEO Pharma obtains positive EMA CHMP opinion for eczema treatment | ||
26.07. | Confo Therapeutics secures €60m funds to progress GPCR-modulating therapies | ||
25.07. | Oisín secures funds to advance treatments for age-related ailments | ||
24.07. | FDA grants RMAT designation to AffyImmune's AIC100 for thyroid cancer | ||
23.07. | Vividion Therapeutics to expand capabilities with new R&D centre in US | ||
22.07. | Apollo Therapeutics and University of Oxford sign drug discovery partnership | ||
19.07. | Diamyd Medical secures FDA fast track status for type 1 diabetes treatment | ||
18.07. | Lynch Regenerative Medicine secures funds to develop skin regeneration solutions | ||
17.07. | Merck KGaA launches GMP-compliant cell culture media line in China | ||
16.07. | US FDA grants RMAT designation for Kyverna's KYV-101 | ||
15.07. | Merck enhances ophthalmology portfolio with EyeBio acquisition | ||
12.07. | Leqembi gains approval for Alzheimer's treatment in Israel | ||
11.07. | Cosette Pharmaceuticals acquires Ambien rights in US | ||
10.07. | Amneal Pharmaceuticals launches ready-to-use injectable FOCINVEZ | ||
09.07. | Adicet Bio's ADI-270 receives FDA Fast Track Designation for kidney cancer treatment | ||
08.07. | EU approves AstraZeneca's Tagrisso combined with chemotherapy for EGFRm NSCLC | ||
05.07. | Alembic receives tentative approval from USFDA for Ivosidenib Tablets | ||
04.07. | Beacon Therapeutics secures $170m to expedite gene therapy development | ||
03.07. | FDA grants fast track status for Full-Life's prostate cancer treatment | ||
02.07. | Signet Therapeutics receives FDA approval for sigx1094 IND application | ||
01.07. | EMA CHMP recommends marketing authorisation for Moderna's RSV vaccine |